BioCentury | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

...agonizes PPARδ, PPARα and PPARγ, in Phase II for NASH; and T3D Therapeutics Inc. has T3D-959...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

...in the clinic fall into this category; the most advanced is the Phase II candidate DB959...
BioCentury | Jun 24, 2013
Company News

Dara BioSciences, T3D deal

...Dara granted T3D exclusive, worldwide rights to develop and commercialize DB959 for $500,000 in initial license...
...testing to treat diabetes and dyslipidemia. T3D said it plans to develop the product as T3D-959...
BioCentury | Nov 21, 2011
Clinical News

DB959: Phase Ib data

...A double-blind, placebo-controlled, dose-escalation, U.S. Phase Ib trial in 32 healthy volunteers showed that once-daily DB959...
...Oct. 15, 2007). Dara BioSciences Inc. (NASDAQ:DARA), Raleigh, N.C. Bayer AG (Xetra:BAY), Leverkusen, Germany Product: DB959...
BioCentury | Apr 11, 2011
Clinical News

DB959: Phase Ib started

...a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate 5, 20 and 100 mg oral DB959...
...Oct. 15, 2007). Dara BioSciences Inc. (NASDAQ:DARA), Raleigh, N.C. Bayer AG (Xetra:BAY), Leverkusen, Germany Product: DB959...
BioCentury | Jan 10, 2011
Clinical News

DB959: Additional Phase I data

...U.S. Phase I trial in 76 healthy volunteers showed that the maximum tolerated dose of DB959...
...dose." The company previously presented data from the trial showing that single ascending-doses of oral DB959...
...Oct. 15, 2007). Dara BioSciences Inc. (NASDAQ:DARA), Raleigh, N.C. Bayer AG (Xetra:BAY), Leverkusen, Germany Product: DB959...
BioCentury | Nov 22, 2010
Clinical News

DB959: Phase I data

...double-blind, U.S. Phase I trial in 76 healthy volunteers showed that single ascending-doses of oral DB959...
...with once-daily dosing. Dara plans to begin a Phase I trial evaluating multiple ascending-doses of DB959...
...Oct. 15, 2007). Dara BioSciences Inc. (NASDAQ:DARA), Raleigh, N.C. Bayer AG (Xetra:BAY), Leverkusen, Germany Product: DB959...
BioCentury | Apr 5, 2010
Clinical News

DB959: Phase I started

...Dara began a single ascending-dose, U.S. Phase I trial to evaluate oral DB959 in about 75...
...Bayer in 2007. Dara BioSciences Inc. (NASDAQ:DARA), Raleigh, N.C. Bayer AG (Xetra:BAY), Leverkusen, Germany Product: DB959...
BioCentury | Nov 16, 2009
Clinical News

Dara BioSciences preclinical data

...In mouse models of diabetes, DB959 significantly lowered blood glucose levels and improved glucose tolerance compared...
...at the Cambridge Healthtech Institute meeting in Boston. Dara BioSciences Inc. (NASDAQ:DARA), Raleigh, N.C. Product: DB959...
BioCentury | Oct 8, 2009
Targets & Mechanisms

New role for Actos in MS

...Dara BioSciences Inc. The company is developing next-generation PPAR agonists, and its lead compound is DB959...
Items per page:
1 - 10 of 15